Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors.

Takafumi Koyama Kan Yonemori Toshio Shimizu Jun Sato Shunsuke Kondo Kazuki Sudo Tatsuya Yoshida Yuki Katsuya Tatsuki Imaizumi Masashi Enomoto Ryoko Seki Noboru Yamamoto

Published in: Cancer research communications (2024)

This study describes the safety/tolerability of FAP-IL2v 10 mg alone and in combination with atezolizumab in Japanese patients with advanced solid tumors; one DLT (hypotension) occurred with FAP-IL2v 15/20 mg. However, dose escalation of FAP-IL2v was not conducted due to early study termination.

Keyphrases

open label
clinical trial